GRAL GRAIL, LLC
Company Analysis
Latest News
🟢 GRAIL is trading 5% up today amid upcoming Galleri conference presentations
GRAIL is trading at $162.00, up 5.14%, as coverage links the rise to upcoming Galleri presentations and FDA review. - On October 5, GRAIL announced it will...
🟢 GRAIL is trading 5% up today after FDA panel endorsed Galleri’s potential benefits
GRAIL is trading at $150.47, up 5.03%, as optimism continues after an FDA advisory panel endorsed Galleri’s potential benefits. - The endorsement is a step...
🟢 GRAIL is trading 5% up today amid broader-market strength
GRAIL is trading at $139.40, up 5.16%, with broader-market strength providing context for the gain. - Major indices are also higher. - The weak September jobs...
🔴 GRAIL is trading 4.3% down today with no clear company-specific catalyst
GRAIL is trading 4.3% lower at $134.07 on October 1, 2026, with no new company-specific announcement clearly explaining the decline. - The latest major...
GRAIL Clears a Major FDA Hurdle for Its Cancer Blood Test — But Can the Stock Keep Climbing Without Insurance Coverage?
Shares of GRAIL surged to $150.24, extending a breathtaking +38% rally since September 22, after an FDA advisory panel gave a decisive thumbs-up to the...
🟢 GRAIL is trading 10% up today after FDA panel favored Galleri
GRAIL is trading at $150.24, up 10.01%, as gains extend after an FDA advisory panel voted in favor of Galleri, its multi-cancer detection test. - On September...
🟢 GRAIL is trading 4.12% up after FDA panel backed Galleri cancer test
GRAIL is trading up 4.12% at $142.19 on September 30, extending gains after the September 23 FDA advisory panel backed its Galleri cancer-detection test. - The...
🟢 GRAIL is trading 5% up today after Canaccord raised its target to $150
GRAIL is trading at $133.20, up 4.97%, after Canaccord Genuity raised its target to $150 from $80 and maintained a Buy rating on September 28. - The outlook...
🔴 GRAIL is trading 4.13% down today with no new company-specific catalyst identified
GRAIL is trading 4.13% down at $120.04, with no new company-specific catalyst identified for September 25, 2026. - On September 23, FDA advisers supported...
🟢 GRAIL is trading 10% up today after FDA panel supported Galleri’s benefit-risk profile
GRAIL is trading 10.21% up at $119.60 after an FDA advisory panel supported Galleri’s benefit-risk profile on September 23, 2026. - Advisers voted 7–2, with...
🟢 GRAIL is trading 5.85% up today after FDA panel backed Galleri’s benefit-risk profile
GRAIL is trading 5.85% up at $114.87 after an FDA advisory panel supported Galleri’s benefit-risk profile for approval on September 23, 2026. - The panel...
🔴 GRAIL is trading 6.5% down in pre-market after investors reassess a mixed FDA panel vote
GRAIL is trading at $101.50, down 6.47%, as investors reassess the mixed September 23, 2026 FDA advisory-panel recommendation. - The panel backed Galleri’s...
🟢 GRAIL is trading 7.6% up in pre-market after FDA panel favored Galleri approval
GRAIL is trading at $116.80, up +7.6%, after a favorable September 23 FDA advisory-panel vote supporting Galleri’s approval. - The panel voted 7–2, with one...
🟢 GRAIL rises 4.2% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
🟢 GRAIL is trading 17.6% up today ahead of September 23 FDA advisory committee review
GRAIL is trading at $95.00, +17.62% (17.6% up) after investors positioned ahead of the September 23 FDA advisory committee review of Galleri’s premarket...
GRAIL Surges 15% as Investors Bet Big on an FDA Panel That Could Make or Break the Blood-Test Cancer Screener — But Is the Market Pricing in a Win It Hasn't Earned?
Shares of GRAIL (GRAL) rocketed 14.6% to $92.60 Monday, capping a weeklong climb from $75.53, as traders placed aggressive bets ahead of a make-or-break...
🟢 GRAIL is trading 14.65% up in pre-market ahead of September 23 FDA Galleri review
GRAIL is trading 14.65% up now at $92.60, with the strongest catalyst appearing to be the FDA advisory committee meeting scheduled for September 23, 2026, to...
🟢 GRAIL rises 5.0% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
GRAIL earns UBS strong buy rating, ahead of key FDA cancer review
UBS Group upgraded GRAIL, LLC to a strong-buy rating on September 12, 2026. The upgrade follows the company's August 5 earnings report. GRAIL reported a...
Manufacturers Life Buys GRAIL Stake, Eyeing 2027 Cancer Test Approval
Manufacturers Life Insurance Company acquired 21,597 shares of GRAIL, Inc. during the second quarter. The new stake is valued at approximately $1.474 million...